Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

Stefano Nistri · European Heart Journal · 2014 · 4.3K citations · Full text

Medicine, Cardiology, Internal Medicine +13

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacotherapy +6

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Steve R. Ommen, Seema Mital, Michael A. Burke et al. · Journal of the American College of Cardiology · 2020 · 682 citations

Medicine, Cardiology, Internal Medicine +13

Monitoring clinical changes in patients with heart failure: A comparison of methods

John A. Spertus, Eric D. Peterson, Mark W. Conard et al. · American Heart Journal · 2005 · 563 citations

Medicine, Cardiology, Internal Medicine +11

Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy

Jenifer Crilley, Ernest Boehm, Edward Blair et al. · Journal of the American College of Cardiology · 2003 · 433 citations

Medicine, Cardiology, Genetics +12